Breast Cancer | Unmet Need | Metastatic HR-Positive / HER2-Negative | US/EU | 2024
The treatment landscape for advanced HR-positive / HER2-negative breast cancer is continually evolving. CDK4/6 inhibitors, such as Pfizer’s Ibrance and Novartis’s Kisqali, are commonly used in combination with endocrine therapy as first-line treatments. These agents have significantly improved outcomes for patients with hormone-receptor-positive tumors. However, there is an urgent need for effective later-line treatments. Several drugs recently gained approval in this setting, including AstraZeneca’s Enhertu (for patients with HER2-low disease) and Menarini’s Orserdu (for ESR1-mutated disease). As competition intensifies, novel therapies that address key unmet needs could offer welcome diversification in the clinic.
- What is the level of satisfaction among U.S and European medical oncologists with current treatments for metastatic HR-positive / HER2-negative breast cancer?
- What key factors influence medical oncologists’ decisions when prescribing treatments for metastatic HR-positive / HER2-negative breast cancer? How do key current therapies perform on these key attributes?
- What are the untapped opportunities and unmet needs in this patient subpopulation?
- What trade-offs are U.S. and European oncologists willing to make regarding cost and clinical features for a new metastatic HR-positive / HER2-negative breast cancer drug?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 62 U.S. and 31 European medical oncologists fielded in February 2024
Key drugs: Ibrance, Kisqali, Verzenio / Verzenios, Everolimus, Piqray, Orserdu, Enhertu
Product description
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Key feature
The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
